216 related articles for article (PubMed ID: 35366141)
1. Targeting lysophosphatidic acid receptor with Ki16425 impedes T cell lymphoma progression through apoptosis induction, glycolysis inhibition, and activation of antitumor immune response.
Gupta VK; Kumar A
Apoptosis; 2022 Jun; 27(5-6):382-400. PubMed ID: 35366141
[TBL] [Abstract][Full Text] [Related]
2. Lysophosphatidic acid promotes survival of T lymphoma cells by altering apoptosis and glucose metabolism.
Gupta VK; Jaiswara PK; Sonker P; Rawat SG; Tiwari RK; Kumar A
Apoptosis; 2020 Feb; 25(1-2):135-150. PubMed ID: 31867678
[TBL] [Abstract][Full Text] [Related]
3. Lysophosphatidic acid receptor 1 antagonist ki16425 blunts abdominal and systemic inflammation in a mouse model of peritoneal sepsis.
Zhao J; Wei J; Weathington N; Jacko AM; Huang H; Tsung A; Zhao Y
Transl Res; 2015 Jul; 166(1):80-8. PubMed ID: 25701366
[TBL] [Abstract][Full Text] [Related]
4. Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice.
Li HY; Oh YS; Choi JW; Jung JY; Jun HS
Kidney Int; 2017 Jun; 91(6):1362-1373. PubMed ID: 28111010
[TBL] [Abstract][Full Text] [Related]
5. Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors.
Ohta H; Sato K; Murata N; Damirin A; Malchinkhuu E; Kon J; Kimura T; Tobo M; Yamazaki Y; Watanabe T; Yagi M; Sato M; Suzuki R; Murooka H; Sakai T; Nishitoba T; Im DS; Nochi H; Tamoto K; Tomura H; Okajima F
Mol Pharmacol; 2003 Oct; 64(4):994-1005. PubMed ID: 14500756
[TBL] [Abstract][Full Text] [Related]
6. Lysophosphatidic acid as a mediator for proinflammatory agonists in a human corneal epithelial cell line.
Zhang Z; Liu Z; Meier KE
Am J Physiol Cell Physiol; 2006 Nov; 291(5):C1089-98. PubMed ID: 16760261
[TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1.
Yamada T; Sato K; Komachi M; Malchinkhuu E; Tobo M; Kimura T; Kuwabara A; Yanagita Y; Ikeya T; Tanahashi Y; Ogawa T; Ohwada S; Morishita Y; Ohta H; Im DS; Tamoto K; Tomura H; Okajima F
J Biol Chem; 2004 Feb; 279(8):6595-605. PubMed ID: 14660630
[TBL] [Abstract][Full Text] [Related]
8. Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin.
Ohashi T; Yamamoto T
Exp Dermatol; 2015 Sep; 24(9):698-702. PubMed ID: 25959255
[TBL] [Abstract][Full Text] [Related]
9. Lysophosphatidic Acid Induces Ligamentum Flavum Hypertrophy Through the LPAR1/Akt Pathway.
Zhou T; Du L; Chen C; Han C; Li X; Qin A; Zhao C; Zhang K; Zhao J
Cell Physiol Biochem; 2018; 45(4):1472-1486. PubMed ID: 29466791
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts.
Radhakrishnan R; Ha JH; Jayaraman M; Liu J; Moxley KM; Isidoro C; Sood AK; Song YS; Dhanasekaran DN
Cancer Lett; 2019 Feb; 442():464-474. PubMed ID: 30503552
[TBL] [Abstract][Full Text] [Related]
11. Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice.
Rancoule C; Attané C; Grès S; Fournel A; Dusaulcy R; Bertrand C; Vinel C; Tréguer K; Prentki M; Valet P; Saulnier-Blache JS
Diabetologia; 2013 Jun; 56(6):1394-402. PubMed ID: 23508306
[TBL] [Abstract][Full Text] [Related]
12. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
[TBL] [Abstract][Full Text] [Related]
13. Pro-fibrotic activity of lysophosphatidic acid in adipose tissue: in vivo and in vitro evidence.
Rancoule C; Viaud M; Gres S; Viguerie N; Decaunes P; Bouloumié A; Langin D; Bascands JL; Valet P; Saulnier-Blache JS
Biochim Biophys Acta; 2014 Jan; 1841(1):88-96. PubMed ID: 24120919
[TBL] [Abstract][Full Text] [Related]
14. Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction by synovial fluid of patients with rheumatoid arthritis in fibroblast-like synovial cells.
Nochi H; Tomura H; Tobo M; Tanaka N; Sato K; Shinozaki T; Kobayashi T; Takagishi K; Ohta H; Okajima F; Tamoto K
J Immunol; 2008 Oct; 181(7):5111-9. PubMed ID: 18802115
[TBL] [Abstract][Full Text] [Related]
15. Dioleoyl phosphatidic acid increases intracellular Ca2+ through endogenous LPA receptors in C6 glioma and L2071 fibroblasts.
Chang YJ; Kim YL; Lee YK; Sacket SJ; Kim K; Kim HL; Han M; Bae YS; Okajima F; Im DS
Prostaglandins Other Lipid Mediat; 2007 Jun; 83(4):268-76. PubMed ID: 17499746
[TBL] [Abstract][Full Text] [Related]
16. Activation of fibroblast-like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid-lysophosphatidic acid receptor 1 cascade.
Miyabe Y; Miyabe C; Iwai Y; Yokoyama W; Sekine C; Sugimoto K; Harigai M; Miyasaka M; Miyasaka N; Nanki T
Arthritis Res Ther; 2014 Oct; 16(5):461. PubMed ID: 25273676
[TBL] [Abstract][Full Text] [Related]
17. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites.
Komachi M; Tomura H; Malchinkhuu E; Tobo M; Mogi C; Yamada T; Kimura T; Kuwabara A; Ohta H; Im DS; Kurose H; Takeyoshi I; Sato K; Okajima F
Carcinogenesis; 2009 Mar; 30(3):457-65. PubMed ID: 19129242
[TBL] [Abstract][Full Text] [Related]
18. Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.
David M; Sahay D; Mege F; Descotes F; Leblanc R; Ribeiro J; Clézardin P; Peyruchaud O
PLoS One; 2014; 9(5):e97771. PubMed ID: 24828490
[TBL] [Abstract][Full Text] [Related]
19. Nimbolide retards T cell lymphoma progression by altering apoptosis, glucose metabolism, pH regulation, and ROS homeostasis.
Jaiswara PK; Kumar A
Environ Toxicol; 2022 Jun; 37(6):1445-1457. PubMed ID: 35199915
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of lysophosphatidic acid receptor ameliorates Sjögren's syndrome in NOD mice.
Park E; Kim D; Lee SM; Jun HS
Oncotarget; 2017 Apr; 8(16):27240-27251. PubMed ID: 28460477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
